Abstract
Spontaneous cases of hepatic adverse events have been reported in patients with rheumatoid arthritis who were being treated with leflunomide, one of the newer disease-modifying antirheumatic drugs (DMARDs). We assessed the risk of hepatic events associated with the use of leflunomide and other DMARDs. Two cohorts comprising 41,885 patients with rheumatoid arthritis who had been dispensed a DMARD between September 1, 1998, and December 31, 2001, were formed using claims databases. Follow-up was from the first dispensing date to the occurrence of a serious or nonserious hepatic event. A nested case-control approach was used to estimate adjusted rate ratios of hepatic events associated with DMARDs dispensed during the prior year, as compared with methotrexate monotherapy. There were 25 cases of serious hepatic events (rate, 4.9 per 10,000 per year) and 411 nonserious hepatic events (rate, 80.0 per 10,000 per year). There was no increase in the rate of serious hepatic events with either leflunomide (rate ratio [RR] = 0.9; 95% confidence interval [CI]: 0.2 to 4.9) or traditional DMARDs (RR = 2.3; 95% CI: 0.8 to 6.5). However, the rate was increased with biologic DMARDs (RR = 5.5; 95% CI: 1.2 to 24.6). The rate of nonserious hepatic ...Continue Reading
References
Mar 23, 2000·Arthritis and Rheumatism·J T SharpI Loew-Friedrich
Nov 18, 2000·Arthritis and Rheumatism·M E WeinblattK R Falchuk
Apr 17, 2001·Annals of Internal Medicine·J M Kremer
Jun 27, 2001·Rheumatology·P EmeryG Seydoux
Sep 15, 2001·Annals of the Rheumatic Diseases·D L ScottUNKNOWN European Leflunomide Study Group
Oct 16, 2002·Annals of the Rheumatic Diseases·D E FurstL Klareskog
Oct 26, 2002·Journal of Hepatology·Luisa IbáñezUNKNOWN Grup d'Estudi Multicènteric d'Hepatotoxicitat Aguda de Barcelona (GEMHAB)
Citations
Nov 27, 2007·Nature Clinical Practice. Rheumatology·Samy Suissa, Edeltraut Garbe
Jan 26, 2011·Nature Reviews. Rheumatology·Guruprasad P Aithal
May 15, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Aaron J KatzPaul E Stang
Dec 18, 2013·Vaccine·Cecilia P ChungMelissa L McPheeters
Jun 12, 2013·Research in Social & Administrative Pharmacy : RSAP·Richard A HansenDavid Mark Carpenter
Jul 9, 2005·Journal of Vascular and Interventional Radiology : JVIR·Thomas JahnkeStefan Müller-Hülsbeck
Nov 30, 2010·Clinics in Liver Disease·Christine SchlenkerKris V Kowdley
May 20, 2008·Gastroentérologie Clinique Et Biologique·D Larrey
May 23, 2007·Pulmonary Pharmacology & Therapeutics·Samy SuissaMarie Hudson
Mar 28, 2009·Pharmacoepidemiology and Drug Safety·Juhaeri JuhaeriWanju S Dai
Dec 22, 2012·Pharmacoepidemiology and Drug Safety·Janet ShinT Craig Cheetham
Jun 7, 2005·Expert Opinion on Pharmacotherapy·J Peter Kaltwasser, Frank Behrens
Oct 11, 2014·Seminars in Arthritis and Rheumatism·Jeffrey R CurtisUNKNOWN Actemra Pharmacoepidemiology Board
Oct 22, 2016·Scandinavian Journal of Rheumatology·Y-M ChiuH-Y Lin
Nov 11, 2011·The Cochrane Database of Systematic Reviews·Alexandra N ColebatchChristopher J Edwards
Apr 29, 2006·Arthritis and Rheumatism·Samy SuissaPierre Ernst
Jul 29, 2006·Arthritis and Rheumatism·Samy SuissaMarie Hudson
Mar 11, 2005·Rheumatology·V GoëbX Le Loët
Dec 1, 2007·Arthritis and Rheumatism·Allison L SmittenK Arnold Chan
Jun 11, 2009·Current Opinion in Organ Transplantation·Nicolae Leca
Nov 18, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Nicola AlcornRajan Madhok
Dec 12, 2018·Archives of Pathology & Laboratory Medicine·Marsha A RaebelIra M Lubin
Jan 1, 2006·Expert Review of Clinical Immunology·Gary Kunkel, Grant W Cannon
May 21, 2019·Population Health Management·Marsha A RaebelIra M Lubin
Nov 7, 2012·Therapeutic Drug Monitoring·Maria Grazia AnelliGiovanni Lapadula
Mar 24, 2005·Rheumatology·S BernatskyS Suissa
Nov 2, 2017·Arthritis Research & Therapy·Ying-Ming ChiuK Arnold Chan